Portraying the spectrum of tumor recurrence mutations in the same patient without the oncogenic lung cancer driver mutations such as EGFR, KRAS, and EML4‐ALK is an integrative step of understanding lung cancer tumor progression. Here, EGFR is linked to lung carcinoma.